Half-year report · Q2
7733.TEDINET S100UNV8
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardIFRS
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥474.0bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥925.8bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥431.6bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥70.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.8bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥68.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥43.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥49.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥242.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥216.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥49.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥216.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.37T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.53T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.62T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥663.6bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥777.0bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥703.1bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥757.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥827.5bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥641.2bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥703.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥757.2bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥827.5bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥245.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥340.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥488.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥93.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥42.4bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥11.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥30.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥360.0bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥412.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥156.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥276.0bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥125.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥42.24 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥199.91 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥173.81 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥42.16 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥199.44 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥173.81 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 51.4% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.4% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 51.2% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥387m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥18.5bn |
| jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥26.8bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥89.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥9m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥18.6bn |
| jpcrp040300-q2r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥50.9bn |
| jpcrp040300-q2r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥28.5bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥22.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 683
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss before tax IFRS | Prior1YTDDuration | -2051000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | -226000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | -8000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_ReportableSegmentsMember | -234000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | -234000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 20537000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 9234000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReportableSegmentsMember | 29771000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 105000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration_ReconcilingItemsMember | 2644000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YTDDuration | 32520000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 138000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 41605000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReportableSegmentsMember | 41743000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration_ReconcilingItemsMember | -4000000 | JPY |
| Impairment losses pl IFRS | Prior1YTDDuration | 41739000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 298706000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 175038000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 473744000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 285000000 | JPY |
| Sales to external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Sales to external customers IFRS | CurrentYTDDuration | 474029000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 59000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 11000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_ReportableSegmentsMember | 70000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Intersegment sales IFRS | CurrentYTDDuration_ReconcilingItemsMember | -70000000 | JPY |
| Intersegment sales IFRS | CurrentYTDDuration | － | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 298765000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 175049000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_ReportableSegmentsMember | 473814000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 285000000 | JPY |
| Net sales IFRS | CurrentYTDDuration_ReconcilingItemsMember | -70000000 | JPY |
| Net sales IFRS | CurrentYTDDuration | 474029000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 62554000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | 26846000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 89400000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -387000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | -18483000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 70530000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 1878000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 3603000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 68805000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000EndoscopicSolutionsReportableSegmentMember | 41000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_jpcrp040300-q2r_E02272-000TherapeuticSolutionsReportableSegmentMember | -22000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_ReportableSegmentsMember | 19000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |